Patents by Inventor Curt Wolfgang

Curt Wolfgang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20220259660
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: April 8, 2022
    Publication date: August 18, 2022
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20190360047
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: May 8, 2019
    Publication date: November 28, 2019
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
  • Method and composition for treating a serotonin receptor-mediated condition
    Patent number: 9987264
    Abstract: A method and composition for treating serotonin receptor-mediated conditions.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: June 5, 2018
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
  • METHOD AND COMPOSITION FOR TREATING A SEROTONIN RECEPTOR-MEDIATED CONDITION
    Publication number: 20160361303
    Abstract: A method and composition for treating serotonin receptor-mediated conditions.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 15, 2016
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
  • Method and composition for treating a serotonin receptor-mediated condition
    Patent number: 9446038
    Abstract: A method and composition for treating serotonin receptor-mediated conditions.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: September 20, 2016
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20160053324
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: September 8, 2015
    Publication date: February 25, 2016
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
  • Methods for the administration of iloperidone
    Patent number: 9138432
    Abstract: The present invention relates to methods for treating a patient with iloperidone or a metabolite thereof, which patient is also being treated with fluoxetine, and lowering risk for QT prolongation.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: September 22, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Curt Wolfgang, Mihael Polymeropoulos
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20140128433
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 8, 2014
    Applicant: Vanda Pharmaceuticals, Inc.
    Inventors: Curt Wolfgang, Mihael Polymeropoulos
  • METHOD AND COMPOSITION FOR TREATING A SEROTONIN RECEPTOR-MEDIATED CONDITION
    Publication number: 20140079685
    Abstract: A method and composition for treating serotonin receptor-mediated conditions.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 20, 2014
    Applicant: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20140045893
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: October 23, 2013
    Publication date: February 13, 2014
    Applicant: Vanda Pharmaceuticals, Inc.
    Inventors: Curt Wolfgang, Mihael Polymeropoulos
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20140039008
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: October 2, 2013
    Publication date: February 6, 2014
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
  • Method and composition for treating a serotonin receptor-mediated condition
    Patent number: 8618134
    Abstract: A method and composition for treating serotonin receptor-mediated conditions.
    Type: Grant
    Filed: December 13, 2008
    Date of Patent: December 31, 2013
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
  • Gene expressed in prostate cancer and methods of use
    Patent number: 7897355
    Abstract: A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specifically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharmaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: March 1, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira H. Pastan, Tapan K. Bera, Curt Wolfgang, Byungkook Lee, James Vincent
  • METHOD AND COMPOSITION FOR TREATING A SERATONIN RECEPTOR-MEDIATED CONDITION
    Publication number: 20110044971
    Abstract: A method and composition for treating serotonin receptor-mediated conditions.
    Type: Application
    Filed: December 13, 2008
    Publication date: February 24, 2011
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
  • Gene expressed in prostate cancer and methods of use
    Patent number: 7816087
    Abstract: A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specfically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharamaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: October 19, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira H. Pastan, Tapan K. Bera, Curt Wolfgang, Byungkook Lee, James Vincent
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20100063093
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: September 10, 2008
    Publication date: March 11, 2010
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
  • GENE EXPRESSED IN PROSTATE CANCER AND METHODS OF USE
    Publication number: 20090202552
    Abstract: A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specifically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharmaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.
    Type: Application
    Filed: August 18, 2008
    Publication date: August 13, 2009
    Inventors: Ira H. Pastan, Tapan K. Bera, Curt Wolfgang, Byungkook Lee, James Vincent
  • Cross-Reference To Related Applications
    Publication number: 20080033053
    Abstract: Adamantane and other agents with similar effects on gene expression are useful in the treatment or prevention of ocular disorders.
    Type: Application
    Filed: July 22, 2005
    Publication date: February 7, 2008
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
  • Biomarkers For The Prediction Of Drug-In Duced Diarrhea
    Publication number: 20070289889
    Abstract: The invention provides biomarkers for the prediction of diarrhoea based upon the gene expression of certain genes by the subject, the expression of the Diego blood type by the subject, or the results of haematological assays.
    Type: Application
    Filed: October 5, 2004
    Publication date: December 20, 2007
    Applicant: NOVARTIS AG
    Inventor: Curt Wolfgang
  • Use Of Genetic Polymorphisms To Predict Drug-Induced Hepatotoxicity
    Publication number: 20070248955
    Abstract: IL1A or a gene located near IL1A on chromosome 2q14 may contribute to hepatotoxicity, as measured by increased serum levels of aspartate transaminase, during N-benzoyl-staurosporine treatment for macular edema. Accordingly, genetic polymorphisms in the IL1A gene are useful as biomarkers for predicting staurosporine derivative-mediated hepatotoxicity.
    Type: Application
    Filed: October 5, 2004
    Publication date: October 25, 2007
    Applicant: NOVARTIS AG
    Inventors: Karen McCullough, Curt Wolfgang